Recent and emerging anti-diabetes targets
Diabetes is a disease that affects over 150 million people worldwide for which there are multiple oral and injectable medications. Because of trends in obesity and sedentary lifestyles, diabetes rates in both developed and developing countries are increasing at an alarming rate. Current medications...
Gespeichert in:
| Veröffentlicht in: | Medicinal research reviews 2009-01, Vol.29 (1), p.125-195 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 195 |
|---|---|
| container_issue | 1 |
| container_start_page | 125 |
| container_title | Medicinal research reviews |
| container_volume | 29 |
| creator | Mohler, Michael L. He, Yali Wu, Zhongzhi Hwang, Dong Jin Miller, Duane D. |
| description | Diabetes is a disease that affects over 150 million people worldwide for which there are multiple oral and injectable medications. Because of trends in obesity and sedentary lifestyles, diabetes rates in both developed and developing countries are increasing at an alarming rate. Current medications are not adequately effective in maintaining long‐term glycemic control in most patients, even when used in combination, leaving diabetics susceptible to developing life threatening and debilitating complications such as cardiovascular disease, blindness, kidney complications, and amputations. Consequently, there is a critical need for more potent pharmacotherapies with novel mechanisms of action. A panel of 20 emerging diabetes targets is presented, and small molecule modulators for each target will be discussed. © 2008 Wiley Periodicals, Inc. Med Res Rev, 29, No. 1, 125–195, 2009 |
| doi_str_mv | 10.1002/med.20142 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_66738683</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>66738683</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3612-ef8bb2205ccb86be1eca0f84504f727735ae7c6cfed7b7fd2832bf8136e83a013</originalsourceid><addsrcrecordid>eNp1kMtOAjEUhhujEUQXvoBhZcJioBd6YWkU0Yg3onHZtJ1TMjozYDtEeXsHB9m5Opd858_Jh9ApwX2CMR0UkPYpJkO6h9oEj1RCCFX7qI1J3QtGeQsdxfiOMSGcsEPUIkpxrka4jXozcFBWXVOmXSggzLNyXg9VlqSZsVBB7FYmzKGKx-jAmzzCybZ20Ov1-OXyJpk-Tm4vL6aJY4LQBLyyllLMnbNKWCDgDPZqyPHQSyol4wakE85DKq30KVWMWq8IE6CYwYR10HmTuwyLzxXEShdZdJDnpoTFKmohJFNCsRrsNaALixgDeL0MWWHCWhOsN1507UX_eqnZs23oym62O3IrogYGDfCV5bD-P0nfj6_-IpPmIosVfO8uTPjQ9YeS67eHiZ4-zzB-Yneash-YNHpB</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>66738683</pqid></control><display><type>article</type><title>Recent and emerging anti-diabetes targets</title><source>Wiley Online Library - AutoHoldings Journals</source><source>MEDLINE</source><creator>Mohler, Michael L. ; He, Yali ; Wu, Zhongzhi ; Hwang, Dong Jin ; Miller, Duane D.</creator><creatorcontrib>Mohler, Michael L. ; He, Yali ; Wu, Zhongzhi ; Hwang, Dong Jin ; Miller, Duane D.</creatorcontrib><description>Diabetes is a disease that affects over 150 million people worldwide for which there are multiple oral and injectable medications. Because of trends in obesity and sedentary lifestyles, diabetes rates in both developed and developing countries are increasing at an alarming rate. Current medications are not adequately effective in maintaining long‐term glycemic control in most patients, even when used in combination, leaving diabetics susceptible to developing life threatening and debilitating complications such as cardiovascular disease, blindness, kidney complications, and amputations. Consequently, there is a critical need for more potent pharmacotherapies with novel mechanisms of action. A panel of 20 emerging diabetes targets is presented, and small molecule modulators for each target will be discussed. © 2008 Wiley Periodicals, Inc. Med Res Rev, 29, No. 1, 125–195, 2009</description><identifier>ISSN: 0198-6325</identifier><identifier>EISSN: 1098-1128</identifier><identifier>DOI: 10.1002/med.20142</identifier><identifier>PMID: 18855890</identifier><language>eng</language><publisher>Hoboken: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>Animals ; anti-diabetic pharmacotherapy ; atherosclerosis ; diabetes ; diabetes mellitus ; Diabetes Mellitus - drug therapy ; Diabetes Mellitus - metabolism ; dyslipidemia ; Humans ; Hypoglycemic Agents - chemistry ; Hypoglycemic Agents - classification ; Hypoglycemic Agents - pharmacology ; Hypoglycemic Agents - therapeutic use ; insulin resistance ; metabolic syndrome ; obesity</subject><ispartof>Medicinal research reviews, 2009-01, Vol.29 (1), p.125-195</ispartof><rights>Copyright © 2008 Wiley Periodicals, Inc.</rights><rights>(c) 2008 Wiley Periodicals, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3612-ef8bb2205ccb86be1eca0f84504f727735ae7c6cfed7b7fd2832bf8136e83a013</citedby><cites>FETCH-LOGICAL-c3612-ef8bb2205ccb86be1eca0f84504f727735ae7c6cfed7b7fd2832bf8136e83a013</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fmed.20142$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fmed.20142$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1416,27922,27923,45572,45573</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18855890$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mohler, Michael L.</creatorcontrib><creatorcontrib>He, Yali</creatorcontrib><creatorcontrib>Wu, Zhongzhi</creatorcontrib><creatorcontrib>Hwang, Dong Jin</creatorcontrib><creatorcontrib>Miller, Duane D.</creatorcontrib><title>Recent and emerging anti-diabetes targets</title><title>Medicinal research reviews</title><addtitle>Med. Res. Rev</addtitle><description>Diabetes is a disease that affects over 150 million people worldwide for which there are multiple oral and injectable medications. Because of trends in obesity and sedentary lifestyles, diabetes rates in both developed and developing countries are increasing at an alarming rate. Current medications are not adequately effective in maintaining long‐term glycemic control in most patients, even when used in combination, leaving diabetics susceptible to developing life threatening and debilitating complications such as cardiovascular disease, blindness, kidney complications, and amputations. Consequently, there is a critical need for more potent pharmacotherapies with novel mechanisms of action. A panel of 20 emerging diabetes targets is presented, and small molecule modulators for each target will be discussed. © 2008 Wiley Periodicals, Inc. Med Res Rev, 29, No. 1, 125–195, 2009</description><subject>Animals</subject><subject>anti-diabetic pharmacotherapy</subject><subject>atherosclerosis</subject><subject>diabetes</subject><subject>diabetes mellitus</subject><subject>Diabetes Mellitus - drug therapy</subject><subject>Diabetes Mellitus - metabolism</subject><subject>dyslipidemia</subject><subject>Humans</subject><subject>Hypoglycemic Agents - chemistry</subject><subject>Hypoglycemic Agents - classification</subject><subject>Hypoglycemic Agents - pharmacology</subject><subject>Hypoglycemic Agents - therapeutic use</subject><subject>insulin resistance</subject><subject>metabolic syndrome</subject><subject>obesity</subject><issn>0198-6325</issn><issn>1098-1128</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kMtOAjEUhhujEUQXvoBhZcJioBd6YWkU0Yg3onHZtJ1TMjozYDtEeXsHB9m5Opd858_Jh9ApwX2CMR0UkPYpJkO6h9oEj1RCCFX7qI1J3QtGeQsdxfiOMSGcsEPUIkpxrka4jXozcFBWXVOmXSggzLNyXg9VlqSZsVBB7FYmzKGKx-jAmzzCybZ20Ov1-OXyJpk-Tm4vL6aJY4LQBLyyllLMnbNKWCDgDPZqyPHQSyol4wakE85DKq30KVWMWq8IE6CYwYR10HmTuwyLzxXEShdZdJDnpoTFKmohJFNCsRrsNaALixgDeL0MWWHCWhOsN1507UX_eqnZs23oym62O3IrogYGDfCV5bD-P0nfj6_-IpPmIosVfO8uTPjQ9YeS67eHiZ4-zzB-Yneash-YNHpB</recordid><startdate>200901</startdate><enddate>200901</enddate><creator>Mohler, Michael L.</creator><creator>He, Yali</creator><creator>Wu, Zhongzhi</creator><creator>Hwang, Dong Jin</creator><creator>Miller, Duane D.</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200901</creationdate><title>Recent and emerging anti-diabetes targets</title><author>Mohler, Michael L. ; He, Yali ; Wu, Zhongzhi ; Hwang, Dong Jin ; Miller, Duane D.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3612-ef8bb2205ccb86be1eca0f84504f727735ae7c6cfed7b7fd2832bf8136e83a013</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Animals</topic><topic>anti-diabetic pharmacotherapy</topic><topic>atherosclerosis</topic><topic>diabetes</topic><topic>diabetes mellitus</topic><topic>Diabetes Mellitus - drug therapy</topic><topic>Diabetes Mellitus - metabolism</topic><topic>dyslipidemia</topic><topic>Humans</topic><topic>Hypoglycemic Agents - chemistry</topic><topic>Hypoglycemic Agents - classification</topic><topic>Hypoglycemic Agents - pharmacology</topic><topic>Hypoglycemic Agents - therapeutic use</topic><topic>insulin resistance</topic><topic>metabolic syndrome</topic><topic>obesity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mohler, Michael L.</creatorcontrib><creatorcontrib>He, Yali</creatorcontrib><creatorcontrib>Wu, Zhongzhi</creatorcontrib><creatorcontrib>Hwang, Dong Jin</creatorcontrib><creatorcontrib>Miller, Duane D.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Medicinal research reviews</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mohler, Michael L.</au><au>He, Yali</au><au>Wu, Zhongzhi</au><au>Hwang, Dong Jin</au><au>Miller, Duane D.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Recent and emerging anti-diabetes targets</atitle><jtitle>Medicinal research reviews</jtitle><addtitle>Med. Res. Rev</addtitle><date>2009-01</date><risdate>2009</risdate><volume>29</volume><issue>1</issue><spage>125</spage><epage>195</epage><pages>125-195</pages><issn>0198-6325</issn><eissn>1098-1128</eissn><abstract>Diabetes is a disease that affects over 150 million people worldwide for which there are multiple oral and injectable medications. Because of trends in obesity and sedentary lifestyles, diabetes rates in both developed and developing countries are increasing at an alarming rate. Current medications are not adequately effective in maintaining long‐term glycemic control in most patients, even when used in combination, leaving diabetics susceptible to developing life threatening and debilitating complications such as cardiovascular disease, blindness, kidney complications, and amputations. Consequently, there is a critical need for more potent pharmacotherapies with novel mechanisms of action. A panel of 20 emerging diabetes targets is presented, and small molecule modulators for each target will be discussed. © 2008 Wiley Periodicals, Inc. Med Res Rev, 29, No. 1, 125–195, 2009</abstract><cop>Hoboken</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>18855890</pmid><doi>10.1002/med.20142</doi><tpages>71</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0198-6325 |
| ispartof | Medicinal research reviews, 2009-01, Vol.29 (1), p.125-195 |
| issn | 0198-6325 1098-1128 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_66738683 |
| source | Wiley Online Library - AutoHoldings Journals; MEDLINE |
| subjects | Animals anti-diabetic pharmacotherapy atherosclerosis diabetes diabetes mellitus Diabetes Mellitus - drug therapy Diabetes Mellitus - metabolism dyslipidemia Humans Hypoglycemic Agents - chemistry Hypoglycemic Agents - classification Hypoglycemic Agents - pharmacology Hypoglycemic Agents - therapeutic use insulin resistance metabolic syndrome obesity |
| title | Recent and emerging anti-diabetes targets |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T03%3A06%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Recent%20and%20emerging%20anti-diabetes%20targets&rft.jtitle=Medicinal%20research%20reviews&rft.au=Mohler,%20Michael%20L.&rft.date=2009-01&rft.volume=29&rft.issue=1&rft.spage=125&rft.epage=195&rft.pages=125-195&rft.issn=0198-6325&rft.eissn=1098-1128&rft_id=info:doi/10.1002/med.20142&rft_dat=%3Cproquest_cross%3E66738683%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=66738683&rft_id=info:pmid/18855890&rfr_iscdi=true |